Linking pages
- AMD sued over allegedly misleading Bulldozer core count | Ars Technica http://arstechnica.com/gadgets/2015/11/amd-sued-over-allegedly-misleading-bulldozer-core-count/ 116 comments
- Blackberry Priv early impressions: This is (currently) not a very good phone | Ars Technica http://arstechnica.com/gadgets/2015/11/two-days-with-the-blackberry-priv-it-needs-to-be-better/ 6 comments
- Treatment saved ~90% of terminal cancer patients, but it has scary side effects | Ars Technica http://arstechnica.com/science/2016/02/treatment-saved-90-of-terminal-cancer-patients-but-it-has-scary-side-effects/ 3 comments
- Custom cancer vaccines safely fight and kill tumors in early human trials | Ars Technica https://arstechnica.com/science/2017/07/custom-cancer-vaccines-safely-fight-and-kill-tumors-in-early-human-trials/ 1 comment
- New molecular scissors cut out lingering HIV—maybe once and for all | Ars Technica http://arstechnica.com/science/2016/02/new-molecular-scissors-cut-out-lingering-hiv-maybe-once-and-for-all/ 0 comments
- Treatment saved ~90% of terminal cancer patients, but it has scary side effects | Ars Technica http://arstechnica.co.uk/science/2016/02/treatment-saved-90-of-terminal-cancer-patients-but-it-has-scary-side-effects/ 0 comments
- Custom cancer vaccines safely fight and kill tumors in early human trials | Ars Technica https://arstechnica.com/science/2017/07/custom-cancer-vaccines-safely-fight-and-kill-tumors-in-early-human-trials/?comments=1 0 comments
Linked pages
- AMD sued over allegedly misleading Bulldozer core count | Ars Technica http://arstechnica.com/gadgets/2015/11/amd-sued-over-allegedly-misleading-bulldozer-core-count/ 116 comments
- Blackberry Priv early impressions: This is (currently) not a very good phone | Ars Technica http://arstechnica.com/gadgets/2015/11/two-days-with-the-blackberry-priv-it-needs-to-be-better/ 6 comments
- http://www.technologyreview.com/featuredstory/538441/biotechs-coming-cancer-cure/ 0 comments
Related searches:
Search whole site: site:arstechnica.com
Search title: First-of-their-kind gene-edited cells treat baby’s leukemia | Ars Technica
See how to search.